UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

431 Biomarkers related to Vanucizumab single agent therapy in serial plasma, tumor tissue and skin wound-healing biopsies of patients with advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S88-S89

2015

Volltextzugriff (PDF)

Co-deposition of salmeterol and fluticasone propionate by a combination inhaler

International journal of pharmaceutics, 2006-04, Vol.313 (1), p.14-22

2006

Volltextzugriff (PDF)

Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179

Annals of oncology, 2017-09, Vol.28, p.v335-v335

2017

Volltextzugriff (PDF)

Changes in depth distribution and activity in small benthic riverine fishes under gradually changing light intensities

Limnetica, 2000-06, Vol.18 (1), p.75-80

Prenda, José

2000

Volltextzugriff (PDF)

Reproductive biology of the mosquitofish in a permanent natural lagoon in south-west Spain: two tactics for one species

Journal of fish biology, 1997-07, Vol.51 (1), p.80-92

1997

Volltextzugriff (PDF)

Species interactions and substrate preferences in three small benthic fishes

Limnetica, 1997-06, Vol.13 (1), p.47-53

Prenda, José

1997

Volltextzugriff (PDF)

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 2018-04, Vol.24 (7), p.1536-1545

2018

Volltextzugriff (PDF)

Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder

Neuropsychopharmacology (New York, N.Y.), 2023-07, Vol.48 (8), p.1201-1216

2023

Volltextzugriff (PDF)

A 6-Month Supervised Employer-Based Minimal Exercise Program for Police Officers Improves Fitness

Journal of strength and conditioning research, 2012-09, Vol.26 (9), p.2338-2344

2012

Volltextzugriff (PDF)

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Translational oncology, 2021-02, Vol.14 (2), p.100984-100984, Article 100984

2021

Volltextzugriff (PDF)

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

Journal of clinical lipidology, 2013-09, Vol.7 (5), p.414-422

2013

Volltextzugriff (PDF)

Personality biomarkers of pathological gambling: A machine learning study

Journal of neuroscience methods, 2018-01, Vol.294, p.7-14

2018

Volltextzugriff (PDF)

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3539-3539

2017

Volltextzugriff (PDF)

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5549-5549

2015

Volltextzugriff (PDF)

Xanthophylls, Phytosterols and Pre-β1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study

Lipids, 2013-12, Vol.48 (12), p.1185-1196

2013

Volltextzugriff (PDF)

Xanthophylls, Phytosterols and Pre-[beta]1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study

Lipids, 2013-12, Vol.48 (12), p.1185

2013

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Humans
(6)
Adult
(5)
Female
(5)
Male
(5)
Middle Aged
(4)
Pharmacology & Pharmacy
(3)
Aged
(2)
Animals
(2)
Biological And Medical Sciences
(2)
Cancer
(2)
Dyslipidemias - Drug Therapy
(2)
Dyslipidemias - Metabolism
(2)
Fenofibrate - Therapeutic Use
(2)
Freshwater
(2)
Hypolipidemic Agents - Therapeutic Use
(2)
Life Sciences
(2)
Microhabitat Preferences
(2)
Neurosciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

431 Biomarkers related to Vanucizumab single agent therapy in serial plasma, tumor tissue and skin wound-healing biopsies of patients with advanced solid tumors

Co-deposition of salmeterol and fluticasone propionate by a combination inhaler

Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179

Changes in depth distribution and activity in small benthic riverine fishes under gradually changing light intensities

Reproductive biology of the mosquitofish in a permanent natural lagoon in south-west Spain: two tactics for one species

Species interactions and substrate preferences in three small benthic fishes

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder

A 6-Month Supervised Employer-Based Minimal Exercise Program for Police Officers Improves Fitness

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Personality biomarkers of pathological gambling: A machine learning study

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC)

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study

Xanthophylls, Phytosterols and Pre-β1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study

Xanthophylls, Phytosterols and Pre-[beta]1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Suchergebnisse filtern